Cumberland Pharmaceuticals Inc Stock Price, News & Analysis

Cumberland (Nasdaq: CPIX) announced a co-commercialization joint venture with RedHill (Nasdaq: RDHL) to jointly commercialize the FDA-approved H. pylori therapy Talicia effective Oct 20, 2025.

Key terms: Cumberland will invest $4.0M, assume U.S. distribution and record sales; Talicia net revenues were $8.0M in 2024; net revenues will be shared 50/50. Product protections include U.S. patents through 2042 and 8 years QIDP exclusivity. Broad coverage and retail access include ~70% commercial and 60% government coverage and stocking at 1,700 CVS pharmacies.

RedHill (NASDAQ: RDHL) announced a strategic partnership with Cumberland Pharmaceuticals (NASDAQ: CPIX) on Oct 20, 2025 in which Cumberland will invest $4.0 million for a 30% ownership stake and joint control of RedHill's Talicia business, with RedHill retaining 70%.

The companies agreed an equal-sharing U.S. co-commercialization deal for Talicia's net revenues, with Cumberland providing national sales, marketing and operational support. Talicia is patent protected through 2042 and holds eight years of U.S. QIDP exclusivity. The transaction also contributes to RedHill's belief that it has stockholders' equity above the $2.5 million Nasdaq continued-listing threshold as of the press release date.

Cumberland Pharmaceuticals (NASDAQ:CPIX) announced that its antibiotic Vibativ (telavancin) was added to a national group purchasing agreement with Premier, Inc., effective October 1, 2025.

Premier membership includes about 4,350 U.S. hospitals and 325,000 other providers; the agreement makes Premier’s pre‑negotiated pricing and terms available to members for Vibativ in both the existing 12‑vial carton and a newly introduced 4‑vial Starter Pak, intended to support inpatient and outpatient ordering flexibility and inventory management.

Cumberland Pharmaceuticals (NASDAQ: CPIX) has received regulatory approval for its injectable ibuprofen product in Mexico through a partnership with PiSA Farmaceutica. The product, designed for pain management and fever reduction in hospital and surgical settings, will be supplied in 800 mg vials.

Under the partnership agreement, Cumberland provides regulatory and manufacturing support, while PiSA led the regulatory process and will handle the product launch in Mexico. The injectable ibuprofen has demonstrated significant benefits in reducing post-operative pain and decreasing opioid medication requirements, supporting multimodal, opioid-sparing pain management strategies.

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Tabuk Pharmaceutical Manufacturing Company have launched Vibativ® (telavancin) injection in Saudi Arabia. This FDA-approved antibiotic is designed to treat hospital-acquired and ventilator-associated pneumonia, including infections from flu and COVID-19, as well as serious skin infections.

The drug specifically targets drug-resistant bacteria, including Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive Staphylococcus aureus (MSSA). Vibativ maintains its potency against difficult-to-treat bacteria even after 10 years since introduction, featuring a unique molecular design that combines lipophilic and hydrophilic components to enhance cell wall penetration and tissue reach.

The launch follows an exclusive agreement granting Tabuk rights to register and promote Vibativ in Saudi Arabia and other Middle Eastern countries.

Cumberland Pharmaceuticals (NASDAQ:CPIX) reported strong financial performance with Q2 2025 revenues of $10.8 million, up 10% year-over-year, and year-to-date revenues of $22.6 million, representing a 23% increase. The company's key developments include the launch of Vibativ® 4-Vial Starter Pak through Vizient Inc., and breakthrough findings from the Phase II FIGHT DMD trial showing 5.4% improvement in cardiac function with ifetroban.

Q2 2025 product revenues included $2.8M for Kristalose®, $3.1M for Sancuso®, $2.7M for Vibativ®, and $1.6M for Caldolor®. The company reported a Q2 net loss of $741,000 but maintained year-to-date net income of $516,000. Cumberland ended Q2 with $68M in total assets, including $16M in cash, and $28M in shareholders' equity.

Cumberland Pharmaceuticals (NASDAQ: CPIX) has secured a significant contract with Vizient, the nation's largest healthcare performance improvement company, for its new Vibativ® 4-Vial Starter Pak. Vizient serves over 65% of U.S. acute care providers, including 97% of academic medical centers.

Vibativ® is an FDA-approved injectable antibiotic for treating hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) and complicated skin infections caused by Gram-positive pathogens, including MRSA. The drug has demonstrated significantly higher cure rates compared to vancomycin in HABP/VABP cases with specific pathogen profiles.

This contract enhances accessibility to Vibativ's new 4-vial configuration, supporting flexible treatment initiation across inpatient and outpatient settings.

Cumberland Pharmaceuticals (NASDAQ: CPIX) announced it will release its Q2 2025 financial results and company update after market close on Tuesday, August 5, 2025, followed by a conference call at 4:30 p.m. Eastern Time.

The company, focused on specialty pharmaceuticals, maintains a portfolio of six FDA-approved products targeting hospital acute care, gastroenterology, and oncology segments. Additionally, Cumberland has ongoing Phase II clinical programs evaluating ifetroban for three conditions: Systemic Sclerosis, Duchenne Muscular Dystrophy-associated cardiomyopathy, and Idiopathic Pulmonary Fibrosis.

Cumberland Pharmaceuticals (NASDAQ: CPIX) presented positive Phase 2 FIGHT DMD trial results for ifetroban, their novel oral therapy for Duchenne muscular dystrophy (DMD) heart disease, at the PPMD conference. The trial showed a significant 5.4% improvement in left ventricular ejection fraction with high-dose ifetroban compared to control groups. The drug demonstrated reduced cardiac damage markers while being well-tolerated, with all patients opting to continue treatment in the open-label extension. Ifetroban, which has received both Orphan Drug and Rare Pediatric Disease Designations from the FDA, works by blocking the thromboxane receptor involved in inflammation and fibrosis. The results are particularly significant as DMD-related heart disease, currently without approved treatments, is the leading cause of death in DMD patients.